Skip to main content

Table 1 Baseline patient characteristics

From: Longitudinal Numbers-Needed-To-Treat (NNT) for Achieving Various Levels of Analgesic Response and Improvement with Etoricoxib, Naproxen, and Placebo in Ankylosing Spondylitis

  Placebo N = 93 Etoricoxib 90 mg N = 103 Etoricoxib 120 mg N = 92 Naproxen 1000 mg N = 99
Age (years), mean (SD) 43.7 (12.1) 43.1 (12.1) 42.5 (12.0) 45.0 (11.4)
Female (%) 20.4 26.2 21.7 20.2
History of iritis (%) 33.3 37.9 31.5 31.3
History of chronic peripheral arthritis (%) 39.8 39.8 39.1 41.4
History of corticosteroid use (%) 32.3 23.3 23.9 22.2
Concomitant DMARD use (%)* 19.4 26.2 19.6 23.2
Baseline BASDAI (100-mm VAS), mean (SD) 54.1 (27.0) 56.9 (22.5) 55.2 (25.1) 54.1 (23.2)
Baseline spine pain (100-mm VAS), mean (SD) 77.2 (15.2) 78.0 (13.9) 78.0 (14.2) 77.2 (16.5)
  1. *Auranofin, azathioprine, cyclosporine, leflunomide, methotrexate, methotrexate sodium, or sulfasalazine
  2. DMARD: disease-modifying antirheumatic drug; SD: standard deviation; VAS: visual analog scale